Monopar Therapeutics (NASDAQ:MNPR) Posts Earnings Results, Misses Expectations By $0.13 EPS

Monopar Therapeutics (NASDAQ:MNPR) announced its quarterly earnings results on Wednesday. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.13), FiscalAI reports.

Monopar Therapeutics Trading Down 0.1%

Monopar Therapeutics stock traded down $0.16 on Wednesday, reaching $114.30. 184,271 shares of the stock were exchanged, compared to its average volume of 221,278. The stock has a market cap of $765.70 million, a PE ratio of -60.16 and a beta of 1.47. Monopar Therapeutics has a twelve month low of $29.18 and a twelve month high of $124.82. The firm has a fifty day moving average price of $92.93 and a two-hundred day moving average price of $70.68.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in MNPR. Russell Investments Group Ltd. acquired a new position in shares of Monopar Therapeutics during the 3rd quarter worth about $28,000. BNP Paribas Financial Markets increased its position in Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after buying an additional 349 shares during the period. Meeder Asset Management Inc. bought a new position in Monopar Therapeutics in the 4th quarter worth approximately $65,000. JPMorgan Chase & Co. lifted its holdings in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Monopar Therapeutics during the second quarter worth approximately $80,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on MNPR shares. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research note on Thursday, July 23rd. Zacks Research raised shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. Wall Street Zen upgraded Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. BTIG Research boosted their price target on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $112.08.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.